share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  08/14 12:43
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial...Show More
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial status, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash from $2.578 million to $59,000. The report also mentions the risks involved in investing in the company's securities and states that the SEC has not approved or disapproved the accuracy or adequacy of the prospectus supplement or the Prospectus.
Panbela Therapeutics，Inc.於2024年8月13日提交了一份招股補充說明書，以更新和補充2024年4月2日以前公佈的招股說明書中的信息，幷包含季度報告的詳細信息。該補充說明書涉及發行875萬股普通股，作爲先前已發行的E類和F類普通股認購權的基礎股份。這些股份最初在一份註冊聲明上註冊，在OTCQb上報價，標的爲「PBLA」。截至2024年8月12日，普通股的最新報價爲每股0.35美元。本補充說明書（包括附帶的季度報告）必須與招股說明書一起閱讀，如有不一致，以補充說明書中的信息爲準。季度報告詳細介紹了公司的財務狀況，包括2024年6月30日止六個月的淨虧損1430萬美元，現金從257.8萬美元降至59000美元。報告還提到投資公司證券涉及的風險，並聲明SEC尚未批准或否認招股補充說明書或招股說明書的準確性或充分性。
Panbela Therapeutics，Inc.於2024年8月13日提交了一份招股補充說明書，以更新和補充2024年4月2日以前公佈的招股說明書中的信息，幷包含季度報告的詳細信息。該補充說明書涉及發行875萬股普通股，作爲先前已發行的E類和F類普通股認購權的基礎股份。這些股份最初在一份註冊聲明上註冊，在OTCQb上報價，標的爲「PBLA」。截至2024年8月12日，普通股的最新報價爲每股0.35美元。本補充說明書（包括附帶的季度報告）必須與招股說明書一起閱讀，如有不一致，以補充說明書中的信息爲準。季度報告詳細介紹了公司的財務狀況，包括2024年6月30日止六個月的淨虧損1430萬美元，現金從257.8萬美元降至59000美元。報告還提到投資公司證券涉及的風險，並聲明SEC尚未批准或否認招股補充說明書或招股說明書的準確性或充分性。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息